New drug strategy may reduce blood transfusions after organ transplants

NCT ID NCT03515447

Completed Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving romiplostim, a drug that boosts platelet production, could reduce the need for platelet transfusions in patients with low platelet counts after heart or lung transplantation or use of heart/lung support devices. Researchers compared a group of 30 patients who received this strategy to a historical group. The goal was to see if fewer transfusions were needed in the first 28 days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: romiplostim
What this could lead to: If successful, this approach could reduce the need for platelet transfusions after heart or lung transplantation, potentially lowering transfusion-related risks.
What could go wrong: This is a small, non-randomized before-after study with only 30 patients, so results may not apply broadly. The strategy may not work for all patients or could have unforeseen side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THROMBOCYTOPENIA

Contacts and locations

Locations

CHU de Nantes

Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.